RT Journal Article
SR Electronic
T1 Use of cytoplasmic 5'nucleotidase for differentiating malignant from benign monoclonal gammopathies.
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 891
OP 892
DO 10.1136/jcp.43.11.891
VO 43
IS 11
A1 Majumdar, G
A1 Heard, S E
A1 Singh, A K
YR 1990
UL http://jcp.bmj.com/content/43/11/891.abstract
AB Bone marrow smears from 15 patients with multiple myeloma, 15 patients with monoclonal gammopathy of undetermined significance (MGUS), and 15 control subjects were examined for the presence of cytoplasmic 5'nucleotidase (c5NT) in plasma cells. Plasma cell positivity for c5NT (mean and 95% confidence interval) in patients with multiple myeloma numbered 46.4% (38.0-54.8%), in those with MGUS it was 15.3% (11.1-19.6%), and in control subjects it was 1.2% (0.3-2.1%). These findings indicate that c5NT can be used to differentiate benign from malignant monoclonal gammopathies.